MARKET

ADCT

ADCT

ADC Therapeutics
NYSE

Real-time Quotes | Nasdaq Last Sale

46.83
+0.33
+0.71%
After Hours: 46.83 0 0.00% 16:00 08/03 EDT
OPEN
46.20
PREV CLOSE
46.50
HIGH
49.09
LOW
46.20
VOLUME
235.93K
TURNOVER
--
52 WEEK HIGH
56.59
52 WEEK LOW
28.50
MARKET CAP
3.23B
P/E (TTM)
-30.8701
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADCT stock price target is 49.00 with a high estimate of 53.00 and a low estimate of 45.00.

EPS

ADCT News

More
Biotech IPOs Capture Record $7.5 Billion in Second Quarter
The popularity of the sector continues with 57 new companies on tap to go public Continue reading...
GuruFocus.com · 07/23 20:42
Dosing underway in ADC Therapeutics' LOTIS 3 combo trial in blood cancer
The first patient has been dosed in ADC Therapeutics' (NYSE:ADCT) Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine
seekingalpha · 07/17 16:36
ADC Therapeutics Announces First Patient Dosed In Pivotal Phase 2 Portion Of LOTIS 3 Clinical Trial Of Loncastuximab Tesirine (Lonca) In Combination With Ibrutinib
Combination is being evaluated in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) Trial is intended to support the submission of a Biologics License Application
Benzinga · 07/17 11:17
ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid
Business Wire · 07/17 11:15
FDA lifts partial hold on mid-stage study of ADC Therapeutics' camidanlumab tesirine
The FDA has removed its partial clinical hold on a pivotal Phase 2 clinical trial evaluating ADC Therapeutics' (NYSE:ADCT) antibody-drug conjugate camidanl
seekingalpha · 07/06 17:10
ADC Therapeutics Announces FDA Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine
LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates
Benzinga · 07/06 11:33
ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine
ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technolo
Business Wire · 07/06 11:30
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
Benzinga · 07/02 12:21

Industry

Biotechnology & Medical Research
+3.91%
Pharmaceuticals & Medical Research
+2.05%

Hot Stocks

Symbol
Price
%Change

About ADCT

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
More

Webull offers kinds of ADC Therapeutics SA stock information, including NYSE:ADCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADCT stock methods without spending real money on the virtual paper trading platform.